Impact of statins on nephrolithiasis in hyperlipidemic patients: A 10-year review of an equal access health care system

Clinical Nephrology

Volumn 79, Issue 5, 2013, Pages 351-355

  Sur, Roger L ^a,b,c,d   Masterson, James H ^d   Palazzi, Kerrin L ^a   L'Esperance, James O ^c,d   Auge, Brian K ^c,d   Chang, David C ^a   Stoller, Marshall L ^e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hyperlipidemia; Nephrolithiasis; Statin; Urinary stone; Urolithiasis; Vascular disease

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; ARMY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE ACCESS; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHROLITHIASIS; OBESITY; OUTPATIENT CARE; PREDICTIVE VALUE; RENAL PROTECTION; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHROLITHIASIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84877668707     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107775     Document Type: Article

References (17)

1. Miller NL, Evan AP, Lingeman JE. Pathogenesis of renal calculi. Urol Clin North Am. 2007; 34: 295-313. doi:10.1016/j.ucl.2007.05.007 PubMed
2. Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008; 35: 369-391. doi:10.1016/j. pop.2008.01.005 PubMed
3. Stoller ML, Meng MV, Abrahams HM, Kane JP. The primary stone event: a new hypothesis involving a vascular etiology. J Urol. 2004; 171: 1920-1924. doi:10.1097/01. ju.0000120291.90839.49 PubMed
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251: 351-364. doi:10.1001/jama.1984.03340270029025 PubMed
5. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68: 1230-1235. doi:10.1111/j.1523-1755.2005.00516.x PubMed
6. Madore F, Stampfer MJ, Willett WC, Speizer FE, Curhan GC. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis. 1998; 32: 802-807. doi:10.1016/S0272-6386(98)70136-2 PubMed
7. Madore F, Stampfer MJ, Rimm EB, Curhan GC. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998; 11: 46-53. doi:10.1016/S0895- 7061(97)00371-3 PubMed
8. Pietrow PK, Preminger GM. Evaluation and medical management of urinary lithiasis. In: Wein AJ, Kavoussi LR, Novick AC et al. (eds). Wein: Campbell-Walsh Urology. Vol 2. 9th ed. Philadelphia, PA: Saunders Elsevier; 2007.
9. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003; 111: 607-616. PubMed
10. Reiner AP, Kahn A, Eisner BH, Pletcher MJ, Sadetsky N, Williams OD, Polak JF, Jacobs DR Jr, Stoller ML. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol. 2011; 185: 920-925. doi:10.1016/j. juro.2010.10.086 PubMed
11. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990; 264: 3018-3024. doi:10.1001/jama.1990.03450230054029 PubMed
12. Holman RL, McGILL HC Jr, Strong JP, Geer JC. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the of the 20th century. Am J Pathol. 1958; 34: 209-235. PubMed
13. Heller HJ, Sakhaee K, Moe OW, Pak CY. Etiological role of estrogen status in renal stone formation. J Urol. 2002; 168: 1923-1927. doi:10.1016/S0022-5347(05)64264-4 PubMed
14. Dey J, Creighton A, Lindberg JS, Fuselier HA, Kok DJ, Cole FE, Hamm LL. Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis. J Urol. 2002; 167: 169-171. doi:10.1016/S0022-5347(05)65405-5 PubMed
15. Scales CD Jr, Curtis LH, Norris RD, Springhart WP, Sur RL, Schulman KA, Preminger GM. Changing gender prevalence of stone disease. J Urol. 2007; 177: 979-982. doi:10.1016/j. juro.2006.10.069 PubMed
16. Nowfar S, Palazzi-Churas K, Chang DC, Sur RL. The relationship of obesity and gender prevalence changes in United States inpatient nephrolithiasis. Urology. 2011; 78: 1029-1033. doi:10.1016/j. urology.2011.04.011 PubMed
17. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005; 293: 455-462. doi:10.1001/jama.293.4.455 PubMed